Posted by Michael Wonder on 03 Dec 2021
AbbVie provides update on Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis in the U.S.
3 December 2021 - AbbVie today announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis.
This update follows a Drug Safety Communication issued on 1 September 2021 by the U.S. FDA following its final review of the post-marketing study, ORAL Surveillance, evaluating Xeljanz (tofacitinib) in patients with rheumatoid arthritis.
